Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Aim 1: To compare the effectiveness of two tobacco treatments that are integrated into
cancer care in producing tobacco abstinence at 6 months.
Aim 2: To explore: a) mechanisms through which treatment promotes abstinence; b)
subpopulations in which abstinence is promoted; and c) which aspects of treatment promote
Aim 3: To compare the incremental cost effectiveness (cost per quit) of two tobacco
Exploratory Aim: To identify the percentage and associated characteristics of smokers who 1)
enroll in tobacco treatment and 2) adhere to tobacco treatment.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Biochemically verified 7-day point prevalence tobacco abstinence at 6 months
The primary endpoint is 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (<15 ng/ml76, 82) or <10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT
Elyse R Park, Ph.D., MPH
Massachusetts General Hospital
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|